NCT02634853 - A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye | Biotech Hunter

Enrollment

429

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

March 31, 2017

Conditions

Keratoconjunctivitis Sicca

Interventions

DRUG

1% Tavilermide Ophthalmic Solution

1% Tavilermide BID Dosing

DRUG

Placebo Ophthalmic Solution

Vehicle Ophthalmic Solution

Trial Locations (2)

MIM-727 Investigational Site, Louisville

MIM-727 Investigational Site, Nashville